94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1554751
This article is part of the Research TopicPathophysiology and Therapeutic Strategies for Oral and Head and Neck CancersView all 10 articles
Exploring the complex role of the Eph/Ephrin signaling in oral and maxillofacial cancers
Provisionally accepted
Reydson Alcides de Lima-Souza1,2
Moisés Willian Aparecido Gonçalves1,2
Raisa Sales de Sá2
Luccas Lavareze1,2
João Figueira Scarini1,2Talita de Carvalho Kimura1,2Fernanda Cristina Poscai Ribeiro3Albina Altemani1Fernanda Viviane Mariano1Gary Chris Fillmore4
Erika Said Abu Egal1,4*- 1Department of Pathology, Faculty of Medical Sciences, State University of Campinas, Campinas, São Paulo, Brazil
- 2Department of Oral Diagnosis, School of Dentistry of Piracicaba, Campinas State University, Piracicaba, Brazil
- 3University of Western São Paulo, Presidente Prudente, Sao Paulo, Brazil
- 4Biorepository and Molecular Pathology, Huntsman Cancer Institute, School of Medicine, The University of Utah, Salt Lake City, Utah, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The Eph (erythropoietin-producing hepatocellular carcinoma) receptor family represents the largest subgroup within the tyrosine kinase receptor family and is recognized for its critical role in regulating the growth, migration, and survival of both normal and malignant cells. The Eph/ephrin signaling has an ambiguous role in squamous cell carcinomas of the oral region, playing both a suppressive and oncogenic role. In salivary gland cancers, the results are reserved, although they suggest that some molecules are associated with a worse prognosis for patients. This review offers a comprehensive summary of the existing literature, underscoring the evidence that supports the involvement of the Eph/ephrin signaling in oral and maxillofacial cancers. Additionally, we examine molecular discoveries that may present promising therapeutic targets for these malignancies.
Keywords: Eph, ephrin, oral squamous cell carcinoma, Salivary gland cancers, target therapy
Received: 02 Jan 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 de Lima-Souza, Gonçalves, de Sá, Lavareze, Scarini, Kimura, Ribeiro, Altemani, Mariano, Fillmore and Egal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Erika Said Abu Egal, Biorepository and Molecular Pathology, Huntsman Cancer Institute, School of Medicine, The University of Utah, Salt Lake City, 84103, Utah, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.